Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies

Apostolia Maria Tsimberidou, Yesid Alvarado, Francis J. Giles*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

68 Scopus citations


Ribonucleotide reductases catalyze the de novo biosynthesis of deoxyribonucleosides for DNA synthesis. Increased ribonucleotide reductases activity has been associated with malignant transformation and tumor cell growth. The ribonucleotide reductases inhibitors may bind with the R1 subunit of the enzyme (Class 1) or the nonheme iron (Class 2). This review focuses on the therapeutic use of ribonucleotide reductases inhibitors in hematologic malignancies. Hydroxyurea, fludarabine and cladribine have established roles in the management of hematologic malignancies, while other ribonucleotide reductases inhibitors, such as gemcitabine, tezacitabine and heterocyclic carboxaldehyde thiosemicarbazones (e.g., triapine) are being evaluated in clinical trials.

Original languageEnglish (US)
Pages (from-to)437-448
Number of pages12
JournalExpert review of anticancer therapy
Issue number4
StatePublished - Aug 2002


  • Hematologic malignancies
  • Inhibitors
  • Ribonucleotide reductase

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology


Dive into the research topics of 'Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies'. Together they form a unique fingerprint.

Cite this